Extended-duration low-intensity apixaban to prevent recurrence in patients with provoked venous thromboembolism and enduring risk factors: rationale and design of the HI-PRO trial - Bikdeli, B; Hogan, H; Morrison, R B (Thromb Haemost, 2022)